文献速递胃肠外科肝胆胰外科围术期管理与 ERAS

手术优先与化疗优先治疗可切除结直肠癌肝转移的比较

Surgery or chemotherapy first? Unveiling the best approach for colorectal cancer with resectable liver metastasis.
PubMed 文献 · Surgery · 2025-06-02

该回顾性研究纳入336例初始可切除同时性结直肠癌肝转移患者,比较手术优先(n=244)与化疗优先(n=92)策略。手术优先组无病生存和总生存均显著优于化疗优先组,围术期靶向治疗与更差生存相关,寡复发局部治疗可改善总生存。

要点

  • 手术优先策略较新辅助化疗改善可切除同时性结直肠癌肝转移的无病生存和总生存。
  • 围术期靶向治疗与更差的无病生存和无进展生存相关。
  • 寡复发接受局部治疗者总生存优于单纯化疗或多复发联合治疗者。

核心结论

  • 手术优先策略较新辅助化疗改善可切除同时性结直肠癌肝转移的无病生存和总生存。
  • 围术期靶向治疗与更差生存相关,寡复发局部治疗改善肿瘤学结局。

研究设计与样本

  • 回顾性分析2007至2022年间336例接受完整根治性切除和围术期化疗的可切除同时性结直肠癌肝转移患者。
  • 患者分为手术优先组(n=244)和化疗优先组(n=92),主要终点为无病生存和总生存。

主要发现

  • 手术优先组无病生存和总生存显著优于化疗优先组。
  • 靶向治疗与更低的无病生存和无进展生存相关。
  • 寡复发接受局部治疗者总生存优于单纯化疗者及多复发接受局部治疗联合化疗或单纯化疗者。

临床怎么用

  • 对初始可切除同时性结直肠癌肝转移可考虑手术优先策略以改善生存。
  • 围术期靶向治疗需权衡生存获益与潜在不良影响。
  • 复发后寡转移患者可考虑局部治疗以改善总生存。

局限性

  • 回顾性研究设计,需前瞻性随机试验验证并细化患者选择标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although neoadjuvant chemotherapy is foundational in treating stage IV colorectal cancer, its effectiveness for patients with resectable colorectal cancer liver metastasis is still under debate. This study evaluates the oncologic outcomes of operation-first compared with chemotherapy-first strategies in patients with initially resectable synchronous colorectal cancer liver metastasis, including the effects of targeted therapy and the survival outcomes after recurrence based on treatment strategy. METHODS: We conducted a retrospective analysis of 336 patients with resectable synchronous colorectal cancer liver metastasis who underwent complete radical resection and perioperative chemotherapy between 2007 and 2022. Patients were divided into operation-first (n = 244) and chemotherapy-first (n = 92) groups. The primary end points were disease-free survival and overall survival. We also explored the impact of targeted therapy and outcomes after recurrence. RESULTS: The operation-first group achieved significantly better disease-free survival and overall survival than the chemotherapy-first group. Targeted therapy was linked with lower disease-free survival and progression-free survival. Patients experiencing oligorecurrence who received local therapy had greater overall survival than those who underwent chemotherapy alone or those with polyrecurrence treated with local therapy plus chemotherapy or chemotherapy alone. CONCLUSION: The operation-first strategy led to improved disease-free and overall survival in comparison with neoadjuvant chemotherapy for patients with resectable synchronous colorectal cancer liver metastasis. Local treatment of oligorecurrence improved oncologic outcomes, whereas perioperative targeted therapies were associated with poorer survival outcomes. These findings indicate the potential advantages of an operation-first approach; however, prospective randomized trials are necessary to verify these findings and to refine patient selection criteria.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Kim S, Shin JK, Park Y, et al. Surgery or chemotherapy first? Unveiling the best approach for colorectal cancer with resectable liver metastasis. Surgery. 2025. PMID: 40460560. doi:10.1016/j.surg.2025.109446

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。